Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial

Journal of Pain

Volumn 13, Issue 5, 2012, Pages 438-449

  Portenoy, Russell K ^a   Ganae Motan, Elena Doina ^b   Allende, Silvia ^c   Yanagihara, Ronald ^d   Shaiova, Lauren ^e   Weinstein, Sharon ^f   McQuade, Robert ^g   Wright, Stephen ^h   Fallon, Marie T ⁱ  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b Emergency Department   (Romania)

^c National Institute of Cancer   (Mexico)

^d Hazel Hawkins Hospital   (United States)

^e METROPOLITAN HOSPITAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^h Porton Down Science Park   (United Kingdom)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; cannabidiol; nabiximols; pain; tetrahydrocannabinol

Indexed keywords

NABIXIMOLS; OPIATE; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOOD; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; TREATMENT OUTCOME; TUMOR GROWTH; WEIGHT REDUCTION; XEROSTOMIA;

AGED; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CANNABIDIOL; CHRONIC PAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 84860660570     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2012.01.003     Document Type: Article

References (33)

1. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N.J. Duez, A. Filiberti, H. Flechtner, S.B. Fleishman, J.C. de Haes, S. Kaasa, M. Klee, D. Osoba, D. Razavi, P.B. Rofe, S. Schraub, K. Sneeuw, M. Sullivan, and F. Takeda The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology J Nat Cancer Inst 85 1993 365 376
2. C. Benedetti, C. Brock, C. Cleeland, N. Coyle, J.E. Dubé, B. Ferrell, S. Hassenbusch III, N.A. Janjan, M.J. Lema, M.H. Levy, M.J. Loscalzo, M. Lynch, C. Muir, L. Oakes, A. O'Neill, R. Payne, K.L. Syrjala, S. Urba, and S.M. Weinstein National Comprehensive Cancer Network. (NCCN) practice guidelines for cancer pain Oncology 14 2000 135 150
3. R. Benyamin, A.M. Trescot, S. Datta, R. Buenaventura, R. Adlaka, N. Sehgal, S.E. Glaser, and R. Vallejo Opioid complications and side effects Pain Physician 11 Suppl 2 2008 S105 S120
4. J.J. Bonica The Management of Pain 1990 Lea and Febiger Philadelphia, PA
5. I. Bushlin, R. Rozenfeld, and L.A. Devi Cannabinoid-opioid interactions during neuropathic pain and analgesia Curr Opin Pharmacol 10 2010 80 86
6. D.B. Carr, L.C. Goudas, E.M. Balk, R. Bloch, J.P.A. Ioannidis, and J. Lau Evidence report on the treatment of pain in cancer patients J Nat Cancer Inst Monogr 32 2004 23 31
7. M. Fallon, and S. McConnell The principles of cancer pain management Clin Med 6 2006 136 139
8. L.C. Goudas, R. Bloch, and M. Gialeli-Goudas The epidemiology of cancer pain Cancer Invest 23 2005 182 190
9. J.R. Johnson, M. Burnell-Nugent, D. Lossignol, E.D. Ganae-Motan, R. Potts, and M.T. Fallon Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain J Pain Symptom Manage 39 2010 167 179
10. I.G. Karniol, and E.A. Carlini Pharmacological interaction between cannabidiol and delta-9-THC Psychopharmacologica 33 1973 53 70
11. I. Krakowski, S. Theobald, L. Balp, M.P. Bonnefoi, G. Chvetzoff, O. Collard, E. Collin, M. Couturier, T. Delorme, R. Duclos, A. Eschalier, B. Fergane, F. Larue, M. Magnet, C. Minello, M.L. Navez, A. Richard, B. Richard, S. Rostaing-Rigattieri, H. Rousselot, N. Santolaria, G. Torloting, S. Toussaint, N. Vuillemin, J.P. Wagner, and N. Fabre FNCLCC: Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002) Br J Cancer 89 Suppl 1 2003 S67 S72
12. D. Lussier, and R.K. Portenoy Adjuvant analgesics in pain management G. Hanks, N. Cherny, N. Christakis, S. Kaasa, M. Fallon, R.K. Portenoy, Oxford Textbook of Palliative Medicine 2010 Oxford University Press Oxford, UK 706 733
13. P. Marquis, C. De La Loge, D. Dubois, A. McDermott, and O. Chassany Development and validation of the Patient Assessment of Constipation Quality of Life Questionnaire Scand J Gastroenterol 40 2005 540 551
14. E. McNicol, N. Horowicz-Mehler, R.A. Fisk, K. Bennett, M. Gialeli-Goudas, P.W. Chew, J. Lau, and D. Carr Management of opioid side effects in cancer-related and chronic non-cancer pain: A systematic review J Pain 4 2003 231 256
15. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br J Psychiatry 134 1979 382 389
16. A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, C. Gasperini, C. Pozzilli, L. Cefaro, G. Comi, P. Rossi, Z. Ambler, Z. Stelmasiak, A. Erdmann, X. Montalban, A. Klimek, and P. Davies Sativex Spasticity Study Group: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis Eur J Neurol 18 2011 1122 1131
17. T.J. Nurmikko, M.G. Serpell, B. Hoggart, P.J. Toomey, B.J. Morlion, and D. Haines Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial Pain 133 2007 210 220
18. O.G. Palesh, J.A. Roscoe, K.M. Mustian, T. Roth, J. Savard, S. Ancoli-Israel, C. Heckler, J.Q. Purnell, M.C. Janelsins, and G.R. Morrow Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program J Clin Oncol 28 2010 292 298
19. R.G. Pertwee Neuropharmacology and therapeutic potential of cannabinoids Addict Biol 5 2000 37 46
20. R.G. Pertwee Cannabinoid pharmacology: The first 66 years Brit J Pharmacol 147 2006 S153 S171
21. R.G. Pertwee Cannabinoids and multiple sclerosis Mol Neurobiol 36 2007 45 59
22. R.K. Portenoy, and P. Lesage Management of cancer pain Lancet 353 1999 1695 1700
23. R.K. Portenoy Treatment of cancer pain Lancet 377 2011 2236 2247
24. I. Reche, J.A. Fuentes, and M. Ruiz-Gayo Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of X and X-opioid receptors Eur J Pharmacol 318 1996 11 16
25. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 2005 812 819
26. F. Salaffi, A. Stancati, C.A. Silvestri, A. Ciapetti, and W. Grassi Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale Eur J Pain 8 2004 283 291
27. F.L. Smith, D. Cichewicz, Z.L. Martin, and S.P. Welch The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol Pharmacol Biochem Behav 60 1998 559 566
28. C. Van Onselen, L.B. Dunn, K. Lee, M. Dodd, T. Koetters, C. West, S.M. Paul, B.E. Auoizerat, W. Wara, P. Swift, and C. Miaskowski Relationship between mood disturbance and sleep quality in oncology outpatients at the initiation of radiation therapy Eur J Oncol Nurs 14 2010 373 379
29. D.T. Wade, C. Collin, C. Stott, and P. Duncombe Meta-analysis of the efficacy and safety of Sativex (nabiximols) on spasticity in people with multiple sclerosis Mult Scler 16 2010 707 714
30. S.P. Welch, and D.L. Stevens Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine in mice J Pharmacol Exp Ther 262 1992 10 18
31. S.P. Welch Interaction of the cannabinoid and opioid systems in the modulation of nociception Int Rev Psychiatry 21 2009 143 151
32. World Health Organisation: International Agency for Research and Cancer. Globocan 2008. Cancer incidence and mortality worldwide in 2008. Available at: http://globocan.iarc.fr. Accessed August 12, 2011
33. A.W. Zuardi, I. Shirakawa, E. Finkelfarb, and I.G. Karniol Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects Psychopharmacology (Berl) 76 1982 245 250